The tweet was deleted by the author.
But we saved everything 🙂.
Patrick Soon-Shiong, a prominent figure in the medical field, recently highlighted the importance of lymphocyte protection in cancer treatment.
In a recent tweet, Soon-Shiong emphasized that Anktiva is being used as an adjunctive therapy that helps safeguard lymphocytes, which are crucial for improving patients' chances of overcoming cancer. He expressed gratitude to Sean and media personality Ryan Seacrest for raising awareness about this revelation.
Soon-Shiong's statement reflects ongoing advancements in oncology, focusing on enhancing existing treatments to fortify patients' immune systems. The involvement of public figures like Sean and Seacrest in promoting awareness plays a vital role in increasing public understanding of cancer therapies and encouraging patient advocacy.
Soon-Shiong’s latest remarks on immunotherapy innovation follow his submission of groundbreaking lung cancer trial data, where findings indicated that PDL1 levels do not affect NK cells during treatment. His continued advocacy for advancing the Cancer Moonshot initiative similarly underscores a longstanding commitment to transforming cancer care through scientific and policy leadership.